One day, two AstraZeneca deals

Share this article:

AstraZeneca expanded the footprint of its biologics arm MedImmune on Tuesday with two announcements: first, that it purchased Spirogen, a private biotech, for $440 million, and second that it joined up with ADC Therapeutics to develop two antibody drug conjugate (ADC) programs.

The ADC deal involves trading $20 million for an equity investment in ADC along with milestone payments. The linkage between the two deals is that Auven Therapeutics is the majority stakeholder in both ADC and Spirogen.

The deals follow AZ's August acquisition of Amplimmune as part of an expansive oncology push.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.